Product
•
New study shows Magtrace is highly effective for SLNB after neoadjuvant therapy (NACT)
A recent meta-analysis has added to the growing body of evidence supporting the Magtrace® lymphatic tracer for use in sentinel lymph node biopsy (SLNB) after neoadjuvant chemotherapy (NACT).
Boland et al (2025) found that the Magtrace® lymphatic tracer performs on par with radioisotope and blue dye for detection accuracy, with the added benefit of identifying more nodes and offering greater procedural flexibility.
The paper assessed outcomes from five studies involving 374 breast cancer patients. All patients received SLNB following NACT, comparing Magtrace (superparamagnetic iron oxide) to the traditional “Gold Standard”.
The key findings:
- High detection accuracy: The Magtrace® lymphatic tracer node detection was successful in 98.1% of patients post-NAC, compared to radioisotope (RI) at 94.6%.
- More nodes retrieved: On average, 2.26 sentinel nodes were identified with the Magtrace® lymphatic tracer versus 1.86 with RI - potentially reducing false-negative rates.
- Flexible timing of injection: Unlike RI, the Magtrace® lymphatic tracer can be injected many weeks ahead of surgery. One study (Pantiora et al, 2024) found pre-NACT injection improved nodal detection, a unique advantage not possible with Technetium.
- Effective in dual-tracer settings: When used alongside RI, the Magtrace® lymphatic tracer showed high concordance, supporting its reliability as a stand-alone or complementary option.
“SPIO [Magtrace] appears to be equally effective as current standard tracers for sentinel lymph node identification and will likely identify a higher number of sentinel lymph nodes”Boland et al (2025)
This study demonstrates that for surgeons undergoing staging post-NACT, Magtrace offers a reliable and radiation-free option, with the added benefit of higher nodal yield and logistical flexibility.
Ready to find out more about Magtrace?